South Korea
· Delayed Price · Currency is KRW Clinomics Statistics
Total Valuation
Clinomics has a market cap or net worth of KRW 20.03 billion. The enterprise value is 48.91 billion.
| Market Cap | 20.03B |
| Enterprise Value | 48.91B |
Important Dates
The next estimated earnings date is Thursday, March 20, 2025.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Clinomics has 38.45 million shares outstanding. The number of shares has increased by 35.71% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 38.45M |
| Shares Change (YoY) | +35.71% |
| Shares Change (QoQ) | +3.84% |
| Owned by Insiders (%) | 7.01% |
| Owned by Institutions (%) | 3.40% |
| Float | 24.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.14 |
| PB Ratio | 0.54 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.43 |
| EV / Sales | 5.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.10 |
Financial Position
The company has a current ratio of 0.32, with a Debt / Equity ratio of 0.85.
| Current Ratio | 0.32 |
| Quick Ratio | 0.09 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.02 |
| Interest Coverage | -9.98 |
Financial Efficiency
Return on equity (ROE) is -68.55% and return on invested capital (ROIC) is -22.02%.
| Return on Equity (ROE) | -68.55% |
| Return on Assets (ROA) | -17.37% |
| Return on Capital (ROIC) | -22.02% |
| Revenue Per Employee | 112.96M |
| Profits Per Employee | -470.12M |
| Employee Count | 73 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 3.35 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.88% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -77.88% |
| 50-Day Moving Average | 581.00 |
| 200-Day Moving Average | 1,283.68 |
| Relative Strength Index (RSI) | 45.01 |
| Average Volume (20 Days) | 1,026,709 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Clinomics had revenue of KRW 8.25 billion and -34.32 billion in losses. Loss per share was -1,012.93.
| Revenue | 8.25B |
| Gross Profit | -25.17M |
| Operating Income | -29.14B |
| Pretax Income | -34.57B |
| Net Income | -34.32B |
| EBITDA | -25.05B |
| EBIT | -29.14B |
| Loss Per Share | -1,012.93 |
Balance Sheet
The company has 3.20 billion in cash and 31.85 billion in debt, giving a net cash position of -28.66 billion or -745.32 per share.
| Cash & Cash Equivalents | 3.20B |
| Total Debt | 31.85B |
| Net Cash | -28.66B |
| Net Cash Per Share | -745.32 |
| Equity (Book Value) | 37.38B |
| Book Value Per Share | 966.28 |
| Working Capital | -35.04B |
Cash Flow
In the last 12 months, operating cash flow was -11.10 billion and capital expenditures -4.67 billion, giving a free cash flow of -15.77 billion.
| Operating Cash Flow | -11.10B |
| Capital Expenditures | -4.67B |
| Free Cash Flow | -15.77B |
| FCF Per Share | -410.18 |
Margins
| Gross Margin | -0.31% |
| Operating Margin | -353.40% |
| Pretax Margin | -419.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Clinomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.71% |
| Shareholder Yield | -35.71% |
| Earnings Yield | -194.42% |
| FCF Yield | -78.73% |
Stock Splits
The last stock split was on August 10, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Aug 10, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
Clinomics has an Altman Z-Score of -1.78. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.78 |
| Piotroski F-Score | n/a |